

Breast Cancer Screening Market is Estimated to Generate a Revenue of US\$ 16,340.5 Million By 2031 | Astute Analytica

CHICAGO, UNITED STATES, August 18, 2023

/EINPresswire.com/ -- The global [Breast Cancer Screening Market](#) is estimated to rise in revenue from [US\\$ 1,000.0 million](#) in 2022 to [US\\$ 16,340.5 million](#) by 2031, registering a [CAGR of 12.5%](#) during the forecast period from 2022 to 2031.

For more information, please contact astuteanalytica@astuteanalytica.com or visit astuteanalytica.com/request-sample/breast-cancer-screening-market

Breast cancer is still a major issue for world health due to its rising prevalence and the possibility of disastrous outcomes if not caught early. The need for breast cancer screening has been progressively increasing in recent years due to factors like greater awareness, advancements in screening technology, and government initiatives to promote early diagnosis.

Improved quality of life, more treatment options, and an improvement in the survival rate are all possible results of the early discovery of breast cancer. The market will expand over the forecast period due to the increased prevalence of breast cancer. According to Breastcancer.org, updated in July 2022, 51,400 new instances of non-invasive (in situ) breast cancer and 287,850 new cases of invasive breast cancer are anticipated to be diagnosed in the United States. The market is likely to expand over the forecast period due to the increased demand for breast cancer screening tests in developing and developed countries.

In order to improve access to breast cancer screening, particularly for underprivileged groups, governments have created screening programs and legislation. For instance, the most recent Positron Emission Tomography (PET) CT scan and 3D Mammography department at Manipal Hospital was opened by Special Chief Secretary MT Krishnababu. The state government of India developed an action plan to guarantee complete cancer screening at the village level. Additionally, the advent of less intrusive and more accurate screening techniques, including magnetic resonance imaging (MRI), breast ultrasound, and digital mammography has increased



the identification of breast cancer.

AI-assisted technology is dominating the global market. For instance, preliminary findings from a Swedish trial published tonight show that Artificial Intelligence can accurately detect 20% more breast tumors from mammograms than conventional screening by radiologists. Businesses on the market are utilizing AI's benefits to enhance medical outcomes. Currently, AI's greatest potential lies in its ability to relieve radiologists of their heavy reading loads.

Diagnostic centers segment is the primary end user in the global market. The segment captured over 34.9% of the market's overall revenue in 2022 and is likely to expand at a compound annual growth rate (CAGR) of 9.2% during the forecast period.

The diagnostic centers segment is the primary end user in the global market. The segment captured over 34.9% of the market's overall revenue in 2022 and is likely to expand at a compound annual growth rate (CAGR) of 9.2% during the forecast period.

The rising need for early identification and consultation among patients with breast cancer is one of the main factors influencing the expansion of diagnostic facilities. The availability of diagnostic centers makes them a practical and accessible choice for patients, particularly in urban areas. Nowadays, a lot of diagnostic facilities take part in breast cancer awareness campaigns, working with charities to advance screening initiatives and inform the public about the value of early detection.

North America dominated the breast cancer screening market, which is known for its sophisticated healthcare system and extensive breast cancer research programs. By 2031, the region's revenue generation capacity is expected to have increased to over 32.6% from its current level of over 31% market share.

North America dominated the breast cancer screening market, which is known for its sophisticated healthcare system and extensive breast cancer research programs. By 2031, the region's revenue generation capacity is expected to have increased to over 32.6% from its current level of over 31% market share.

North America stands out as a beacon of innovation and success in the dynamic healthcare scene. Its dominant position is supported by its extensive research initiatives, first-rate medical facilities, and considerable market share in the global fight against breast cancer.

The sad truth is that, behind heart disease, cancer is the second-leading cause of mortality in the US. As a result, the market for breast cancer screening in this nation has seen a large increase in income. According to the American Cancer Society, the US is expected to see 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in 2022 alone. That amounts to a startling daily average of nearly 1,670 deaths.

According to press reports from May 2022, the United States National Breast Cancer Foundation (NBCF) announced financing of more than USD 12.4 million for 20 research initiatives as part of a goal to achieve "zero fatalities from breast cancer" by 2030. Goals to minimize breast cancer are anticipated to fuel market expansion in the region.

□□□□□□ □□ □□□□ □□□□ □□□□□□□□ □□□□□□@- <https://www.astuteanalytica.com/industry-report/breast-cancer-screening-market>

□□□□□□□□□□□□ □□□□□□□□□□

There are several significant companies in the market for breast cancer screening, which is moderately competitive. In terms of market share, a select few significant businesses now dominate the market. Siemens Healthcare, Roche Diagnostics, General Electric Company, and Hologic Inc. are a few of the major market participants that have sizable market shares in the breast cancer screening market.

A few other smaller firms are anticipated to enter the market and may eventually hold a sizable proportion due to rising public awareness and advancements in screening tests.

□□□□□□□□□□□□ □□□□□□□□

□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□ □□ □□□□ □□□□, □□□ □□□□, □□□ □□□□□□.

□□ □□□□ □□□□

- Imaging Tests
 - Ultrasound
 - MRI
 - Mammogram
 - o Film mammography
 - o Digital mammography
 - o Digital breast tomosynthesis (DBT)
- Genetic Tests
- Other screening Tests (Breast Exam, Thermography, Tissue sampling)

□□ □□□ □□□□

- Research Labs
- Cancer Institutes
- Diagnostics Centers
- Others

□□ □□□□□□

- North America
 - o The U.S.
 - o Canada
 - o Mexico
- Europe
 - o Western Europe
 - The UK
 - Germany

- France
- Italy
- Spain
- o Rest of Western Europe
- Eastern Europe
- Poland
- Russia
- o Rest of Eastern Europe
- Asia Pacific
- o China
- o India
- o Japan
- o Australia & New Zealand
- o South Korea
- o ASEAN
- o Rest of Asia Pacific
- Middle East & Africa (MEA)
- o Saudi Arabia
- o South Africa
- o UAE
- o Rest of MEA
- South America
- o Argentina
- o Brazil
- o Rest of South America

□□□□□□□□ □□□□□□□□ □□□□□□ □□□□ □□ □□□□□□□□□□ □□□□□□@- astuteanalytica.com/request-sample/breast-cancer-screening-market

□□□□□□ □□□□□□□□□□□□□□□□:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is

possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg

Astute Analytica

+1 888-429-6757

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/650639980>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.